Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer.

PFS analysis by quartiles of PLCγ1 expression [Q1 (0%–25%), Q2 (25%–50%), Q3 (50%–75%), and Q4 (75%–100%)] showed a significant trend that higher-expression patients progress faster under cetuximab therapy (log-rank test for trend, * P = 0.0340), with a clear distinction between Q1–2 versus Q3–4 patients (Supplementary Fig.

also in 9,356 other papers